Maximo F. Nougues net worth and biography

Maximo Nougues Biography and Net Worth

CFO of Puma Biotechnology

Mr. Nougues joined Puma Biotechnology as Chief Financial Officer in November 2018.

Mr. Nougues worked for Getinge AB, a global medical device company based in Sweden, from January 2008 until October 2018. At Getinge, he held several leadership positions with oversight for the business that generated regional revenues of approximately $1 billion annually. During his tenure at Getinge, he served as regional chief financial officer for North America, regional chief financial officer for the Americas, and regional vice president and chief financial officer for MAQUET North America, which was acquired by Getinge in 2000. Prior to joining Getinge, Mr. Nougues worked in finance roles in Boston Scientific’s cardiac surgery division, which was acquired by Getinge in 2008, and at The Clorox Company from 1998 until 2007.

Mr. Nougues holds an M.S. in business administration from the Universidad del Norte Santo Tomas de Aquino, Tucuman, Argentina and an M.B.A. from the University of San Francisco McLaren School of Business.

What is Maximo F. Nougues' net worth?: The estimated net worth of Maximo F. Nougues is at least $519,257.79 as of July 17th, 2024. Mr. Nougues owns 162,522 shares of Puma Biotechnology stock worth more than $519,258 as of March 26th. This net worth estimate does not reflect any other assets that Mr. Nougues may own. Additionally, Mr. Nougues receives an annual salary of $716,200.00 as CFO at Puma Biotechnology. Learn More about Maximo F. Nougues' net worth.
How old is Maximo F. Nougues?: Mr. Nougues is currently 55 years old. There are 3 older executives and no younger executives at Puma Biotechnology. The oldest executive at Puma Biotechnology is Mr. Douglas Hunt B.Sc., FRAPS, Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer, who is 59 years old. Learn More on Maximo F. Nougues' age.
What is Maximo F. Nougues' salary?: As the CFO of Puma Biotechnology, Inc., Mr. Nougues earns $716,200.00 per year. There are 2 executives that earn more than Mr. Nougues. The highest earning executive at Puma Biotechnology is Mr. Alan H. Auerbach, Founder, Chairman, President, CEO & Secretary, who commands a salary of $1,300,000.00 per year. Learn More on Maximo F. Nougues' salary.
How do I contact Maximo F. Nougues?: The corporate mailing address for Mr. Nougues and other Puma Biotechnology executives is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. Puma Biotechnology can also be reached via phone at (424) 248-6500 and via email at ir@pumabiotechnology.com. Learn More on Maximo F. Nougues' contact information.
Has Maximo F. Nougues been buying or selling shares of Puma Biotechnology?: Maximo F. Nougues has not been actively trading shares of Puma Biotechnology during the last quarter. Most recently, Maximo F. Nougues sold 4,156 shares of the business's stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $3.70, for a transaction totalling $15,377.20. Following the completion of the sale, the chief financial officer now directly owns 162,522 shares of the company's stock, valued at $601,331.40. Learn More on Maximo F. Nougues' trading history.
Who are Puma Biotechnology's active insiders?: Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Douglas Hunt (Insider), Ann Miller (Director), Maximo Nougues (CFO), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.
Are insiders buying or selling shares of Puma Biotechnology?: During the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 152,541 shares worth more than $512,704.29. The most recent insider tranaction occured on January, 2nd when insider Jeffrey Jerome Ludwig sold 9,437 shares worth more than $29,726.55. Insiders at Puma Biotechnology own 23.7% of the company. Learn More about insider trades at Puma Biotechnology.
Information on this page was last updated on 1/2/2025.

Maximo F. Nougues Insider Trading History at Puma Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/17/2024	Sell	4,156	$3.70	$15,377.20	162,522
7/2/2024	Sell	5,295	$3.27	$17,314.65	166,678
1/3/2024	Sell	15,682	$4.49	$70,412.18	128,666
7/3/2023	Sell	14,680	$3.31	$48,590.80	144,348
1/3/2023	Sell	10,499	$4.18	$43,885.82	100,427
11/2/2022	Sell	163	$2.25	$366.75	111,085
10/3/2022	Sell	165	$2.34	$386.10	111,248
8/2/2022	Sell	161	$2.89	$465.29	111,577
7/5/2022	Sell	5,835	$2.63	$15,346.05	64,625
6/2/2022	Sell	162	$1.92	$311.04	121,066
5/3/2022	Sell	165	$2.34	$386.10	121,228
3/2/2022	Sell	169	$2.26	$381.94
2/2/2022	Sell	199	$2.48	$493.52
1/3/2022	Sell	7,484	$3.19	$23,873.96
12/2/2021	Sell	162	$2.95	$477.90
11/2/2021	Sell	156	$5.67	$884.52
10/4/2021	Sell	161	$6.20	$998.20
9/2/2021	Sell	155	$7.51	$1,164.05
8/2/2021	Sell	154	$7.54	$1,161.16
7/2/2021	Sell	155	$9.26	$1,435.30
5/3/2021	Sell	152	$9.91	$1,506.32	68,370
4/5/2021	Sell	155	$9.80	$1,519.00	68,522
1/4/2021	Sell	2,145	$10.22	$21,921.90	13,415

See Full Table

Maximo F. Nougues Buying and Selling Activity at Puma Biotechnology

Puma Biotechnology Company Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Today's Range

Now: $3.20

$3.16

$3.33

50 Day Range

MA: $3.10

$2.76

$3.62

2 Week Range

Now: $3.20

$2.23

$6.06

Volume

130,660 shs

Average Volume

439,622 shs

Market Capitalization

$158.51 million

P/E Ratio

6.66

Dividend Yield

N/A

Beta

1.33

Maximo Nougues Biography and Net Worth

What is Maximo F. Nougues' net worth?

How old is Maximo F. Nougues?

What is Maximo F. Nougues' salary?

How do I contact Maximo F. Nougues?

Has Maximo F. Nougues been buying or selling shares of Puma Biotechnology?

Who are Puma Biotechnology's active insiders?

Are insiders buying or selling shares of Puma Biotechnology?